Literature DB >> 12086495

Synthesis and pharmacology of benzoxazines as highly selective antagonists at M(4) muscarinic receptors.

Thomas M Böhme1, Corinne E Augelli-Szafran, Hussein Hallak, Thomas Pugsley, Kevin Serpa, Roy D Schwarz.   

Abstract

Previously, we reported on PD 102807 (41) as being the most selective synthetic M(4) muscarinic antagonist identified to date. Synthesized analogues of 41 showed no improvement in affinity and selectivity at that time. However, several newly synthesized compounds exhibit a 7-fold higher affinity at M(4) receptors and demonstrate a selectivity of at least 100-fold over all other muscarinic receptor subtypes. For example, compound 28 showed an affinity of pK(i) = 9.00 at M(4) receptors and a selectivity of M(1)/M(4) = 13 183-fold, M(2)/M(4) = 339-fold, M(3)/M(4) = 151-fold, and M(5)/M(4) = 11 220-fold. This high selectivity along with high affinity has not been reported for any synthetic muscarinic antagonist, nor for natural occurring M(4) antagonists such as the M(4) selective Eastern Green Mamba venom MT3 (M(4) pK(b) = 8.7, M(1)/M(4) = 40-fold, M(2)/M(4) > or = 500-fold, M(3)/M(4) > or = 500-fold, and M(5)/M(4) > or = 500-fold). Derivative 24, a compound with a high selectivity pattern as well, has been tested for in vivo efficacy. It was able to block the L-3,4-dihydroxyphenylalanine accumulation produced by CI-1017, an M(1)/M(4) selective muscarinic agonist, in the mesolimbic region and striatum, which suggests that 24 is capable of crossing the blood-brain barrier and confirms the pharmacokinetic data obtained on this compound. This is evidence that suggests that agonist-induced increase in catecholamine synthesis observed in these regions is mediated by M(4) receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086495     DOI: 10.1021/jm011116o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Identification of muscarinic receptor subtypes involved in catecholamine secretion in adrenal medullary chromaffin cells by genetic deletion.

Authors:  Keita Harada; Hidetada Matsuoka; Hironori Miyata; Minoru Matsui; Masumi Inoue
Journal:  Br J Pharmacol       Date:  2015-01-08       Impact factor: 8.739

Review 2.  Functional M3 muscarinic acetylcholine receptors in mammalian hearts.

Authors:  Zhiguo Wang; Hong Shi; Huizhen Wang
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

3.  Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors.

Authors:  Gaurang Trivedi; Daichi Inoue; Cynthia Chen; Lillian Bitner; Young Rock Chung; Justin Taylor; Mithat Gönen; Jürgen Wess; Omar Abdel-Wahab; Lingbo Zhang
Journal:  Sci Transl Med       Date:  2019-09-25       Impact factor: 17.956

4.  Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype.

Authors:  Aaron M Bender; Rebecca L Weiner; Vincent B Luscombe; Hyekyung P Cho; Colleen M Niswender; Darren W Engers; Thomas M Bridges; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-04-04       Impact factor: 2.823

5.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

6.  Pharmacological characterization of muscarinic receptor subtypes mediating vasoconstriction of human umbilical vein.

Authors:  Virginia Andrea Pujol Lereis; Francisco Javier Hita; Mauro Darío Gobbi; Marcela Gomez Verdi; María Cecilia Rodriguez; Rodolfo Pedro Rothlin
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

7.  Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist.

Authors:  Matthew Spock; Trever R Carter; Katrina A Bollinger; Changho Han; Logan A Baker; Alice L Rodriguez; Li Peng; Jonathan W Dickerson; Aidong Qi; Jerri M Rook; Jordan C O'Neill; Katherine J Watson; Sichen Chang; Thomas M Bridges; Julie L Engers; Darren W Engers; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Aaron M Bender
Journal:  ACS Med Chem Lett       Date:  2021-08-02       Impact factor: 4.632

8.  Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists.

Authors:  Guangrong Zheng; Andrew M Smith; Xiaoqin Huang; Karunai L Subramanian; Kiran B Siripurapu; Agripina Deaciuc; Chang-Guo Zhan; Linda P Dwoskin
Journal:  J Med Chem       Date:  2013-02-18       Impact factor: 7.446

Review 9.  M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Shangtong Jiang; Yanfang Li; Cuilin Zhang; Yingjun Zhao; Guojun Bu; Huaxi Xu; Yun-Wu Zhang
Journal:  Neurosci Bull       Date:  2014-03-03       Impact factor: 5.203

10.  Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy.

Authors:  Mark S Moehle; Aaron M Bender; Jonathan W Dickerson; Daniel J Foster; Aidong Qi; Hyekyung P Cho; Yuping Donsante; Weimin Peng; Zoey Bryant; Kaylee J Stillwell; Thomas M Bridges; Sichen Chang; Katherine J Watson; Jordan C O'Neill; Julie L Engers; Li Peng; Alice L Rodriguez; Colleen M Niswender; Craig W Lindsley; Ellen J Hess; P Jeffrey Conn; Jerri M Rook
Journal:  ACS Pharmacol Transl Sci       Date:  2021-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.